​Lexaria's DehydraTECH Overcomes Key Hurdles for Cannabis Extracts

Spotlight Companies  |

Lexaria Bioscience Inc.  (LXX:CNX)(LXRP)) is looking to address the shortcomings of precise dosing across a wide range of delivery systems with its DehydraTECH™ drug delivery platform. By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the bitter and earthy taste of cannabis oil and ensures quick and effective transportation into the bloodstream without degradation in the stomach or liver. Lexaria’s technology now has over 40 patents pending and four patents already granted in the US.

Cannabis oils and extracts have become tremendously popular following the legalization of medical and recreational cannabis across a growing number of jurisdictions. In addition to avoiding the health risks of smoking, cannabis oils and extracts enable patients and consumers to access precise dosing across a wide range of delivery systems (e.g. capsules, vape oil, or edibles) for a consistent experience every time.

Masking Poor Taste

The taste of cannabis oils and extracts depends on the process used to extract the cannabinoids from the plant but it’s generally described as earthy and bitter. In fact, new patients and consumers commonly ask how they can mask the taste of the drug. Many people recommend taking cannabis oils and extracts with breath mints or other products, but the process can be inconvenient at best and ineffective at worst.

Lexaria’s DehydraTECH™ technology masks the earthy and bitter flavors of cannabis oils and extracts using fatty acids. These fatty acids are believed to block and shunt bound ingredients away from bitter taste receptors, which eliminates the bad taste in products that incorporate the technology. Non-active ingredients can then be added to re-flavor the cannabis oils and extracts to make them more palatable for patients and consumers.

For example, Nuka Enterprises LLC signed a licensing agreement earlier this year for its cannabis-infused line of chocolates and edible products. The company had already been utilizing Lexaria’s technology in its award-winning 1906 brand of chocolates for about two years to mask cannabis flavors and ensure a great taste -- along with the many other benefits of Lexaria’s DehydraTECH™ platform.

Improving Bioavailability

Cannabinoids have poor bioavailability for a couple different reasons: Orally-consumed cannabinoids are largely destroyed by stomach acids, and those that aren’t are broken down and altered by first pass metabolism in the liver. This is why smoking cannabis has a much more immediate effect than orally-consumed cannabis; it avoids first-pass metabolism and is more quickly absorbed into the bloodstream through the lungs.

Lexaria’s DehydraTECH™ technology protects orally-consumed cannabinoids during the stomach transit by co-joining them with lipids. At the same time, the long-chain fatty acids bypass first pass liver metabolism by design, enabling the cannabinoids to remain intact upon delivery to the bloodstream. These two features help increase the bioavailability of cannabinoids and ultimately make them more effective for medical cannabis patients or recreational users, and also allow the edible experience to more closely mimic the smoked experience, for the first time ever.

Management has found that DehydraTECH™ reduces the onset time for cannabis oils and extracts to just 15 to 20 minutes compared to 60 to 120 minutes for traditional oral cannabinoids. At the same time, bio absorption improves by five to 10 times to match that of inhaled cannabinoid delivery mechanisms. These attributes make the technology ideal for medical uses cases where precise dosing and immediate onset are critical.

Lexaria’s technology has been repeatedly evaluated by invivo, invitro and human studies and is currently undergoing additional evaluation by Canada’s National Research Council.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
LXRP Lexaria Bioscience Corp. 1.30 -0.07 -5.11 108,588
LXX:CNX Lexaria Bioscience Corp 1.70 -0.12 -6.59 36,055

Comments

Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.